Employees: 11 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2002-02-18 (24 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PACY-SUR-EURE (27120), Eure
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE BOUDET CRAMOISAN : revenue, balance sheet and financial ratios
PHARMACIE BOUDET CRAMOISAN is a French company
founded 24 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PACY-SUR-EURE (27120),
this company of category PME
shows in 2023 a revenue of 3.8 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE BOUDET CRAMOISAN (SIREN 440988731)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
3 844 191 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
50 755 €
32 587 €
30 264 €
185 287 €
71 662 €
96 699 €
125 187 €
121 209 €
117 614 €
EBITDA
N/C
N/C
81 634 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
0.8%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE BOUDET CRAMOISAN generates positive net income of 51 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 118 k€ -> 51 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
50 755 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 1%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 85%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
0.968%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
85.157%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
19.929
11.675
8.021
6.486
5.34
3.681
2.357
0.978
0.968
Financial autonomy
74.008
76.177
80.338
83.718
82.158
82.172
84.661
83.794
85.157
Repayment capacity
None
None
None
None
None
None
0.719
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
1.875%
None%
None%
Sector positioning
Debt ratio
0.972025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Excellent
In 2025, the debt ratio of PHARMACIE BOUDET CRAMOISAN (0.97) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
85.16%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Excellent+10 pts over 3 years
In 2025, the financial autonomy of PHARMACIE BOUDET CRAMOISAN (85.2%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
0.72 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Excellent
In 2023, the repayment capacity of PHARMACIE BOUDET CRAMOISAN (0.72) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 170.86. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
140.945
118.975
137.541
162.253
156.467
180.275
189.49
167.939
170.856
Interest coverage
None
None
None
None
None
None
1.275
None
None
Sector positioning
Liquidity ratio
170.862025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average-6 pts over 3 years
In 2025, the liquidity ratio of PHARMACIE BOUDET CRAMOISAN (170.86) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
1.27x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of PHARMACIE BOUDET CRAMOISAN (1.3x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE BOUDET CRAMOISAN
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
446 657 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
24
0
0
Customer payment term (days)
0
0
0
0
0
0
3
0
0
Supplier payment term (days)
0
0
0
0
0
0
25
0
0
Positioning of PHARMACIE BOUDET CRAMOISAN in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE BOUDET CRAMOISAN is estimated at
806 249 €
(range 547 124€ - 1 265 116€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
547k€806k€1265k€
806 249 €Range: 547 124€ - 1 265 116€
NAF 5 année 2025
Valuation method used
Net Income Multiple
50 755 €
×
15.9x
=806 249 €
Range: 547 125€ - 1 265 116€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE BOUDET CRAMOISAN with other companies in the same sector:
Frequently asked questions about PHARMACIE BOUDET CRAMOISAN
What is the revenue of PHARMACIE BOUDET CRAMOISAN ?
The revenue of PHARMACIE BOUDET CRAMOISAN in 2023 is 3.8 M€.
Is PHARMACIE BOUDET CRAMOISAN profitable?
Yes, PHARMACIE BOUDET CRAMOISAN generated a net profit of 51 k€ in 2025.
Where is the headquarters of PHARMACIE BOUDET CRAMOISAN ?
The headquarters of PHARMACIE BOUDET CRAMOISAN is located in PACY-SUR-EURE (27120), in the department Eure.
Where to find the tax return of PHARMACIE BOUDET CRAMOISAN ?
The tax return of PHARMACIE BOUDET CRAMOISAN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE BOUDET CRAMOISAN operate?
PHARMACIE BOUDET CRAMOISAN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart